ArcticZymes Technologies has signed an agreement with ShareLab AS to lease laboratory facilities at its premises in the Oslo Science Park. These facilities will support application development activities to demonstrate the utility of the Company's enzymes in customer relevant workflows and technologies. This is an essential part of the innovation process and strengthens the commercial value proposition of the Company's product offerings.

ShareLab is a service platform provider of laboratory and office facilities to biotechnology companies. It conveniently provides the necessary amenities and shared core equipment suited to ArcticZymes' requirements which means minimal capital investments to get started. Furthermore, ShareLab's location in the Oslo Science Park is central to the Norwegian biotechnology industry and life science research.

The Oslo location will allow access to a broad talent pool of commercially-experienced application scientists. Also, as the Company continues to grow it has strategic relevance to have part of ArcticZymes located at the heart of the Norwegian biotech industry.

Dr. Darren Ellis has been hired to lead the activities at ShareLab and is currently recruiting two application scientists. Dr. Ellis brings over 20 years of industrial R&D experience (from Solexa (now Illumina) and Thermo Fisher Scientific) in leading and developing molecular research and In Vitro Diagnostic (IVD) applications, technologies, and products.  Furthermore, he has global expertise in Business-to-Business (B2B) application development, successfully helping commercial partners/customers to bring their technologies and product developments to market.

ArcticZymes Technologies ASA, CEO, Jethro Holter said:

"ArcticZymes is delighted to welcome Dr. Ellis to lead this important expansion into Oslo. The new applications team and laboratory are integral to the Company's growth strategy to broaden the utility and relevance of ArcticZymes' enzymes to its commercial customers.

ArcticZymes is proud to partner with ShareLab and become an active member of the Oslo Biotech community."

ShareLab AS, Managing Partner, Esben A. Nilssen, said:

"ArcticZymes is Norway's premier industrial biotech company, and we are both happy and proud to welcome them as new members of ShareLab. At ShareLab, ArcticZymes will benefit from the interaction with biotech talents, life science institutions, and companies located at and around ShareLab and Oslo Science Park. Deep enzymes expertise is much sought after and ArcticZymes' presence at ShareLab will undoubtedly cater for growth."

For more information, please contact:

ArcticZymes Technologies
CEO, Jethro Holter Tel: +47 46 85 91 46
CFO, Børge Sørvoll Tel: +47 95 29 01 87
ir@arcticzymes.com
ShareLab
Managing Partner, Esben A. Nilssen hello@sharelab.no
(ShareLab mailroom)

About ArcticZymes Technologies ASA

ArcticZymes Technologies is a Norwegian life sciences company focused on the development, manufacturing and commercialization of novel recombinant enzymes for use in molecular research, In Vitro Diagnostics (IVD) and therapeutics.

Listed on the Oslo Stock Exchange since 2005 originally under the [Biotec] ticker, as Biotec Pharmacon. The company rebranded as ArcticZymes Technologies in 2020 under the [AZT] ticker. Its headquarters are based in Tromsø, Norway, at the SIVA Innovation Centre.

ArcticZymes Technologies' IP and capabilities are protected via a large portfolio of patents.

For more information, please visit the website: www.arcticzymes.com.

About ShareLab AS

ShareLab offers fully equipped and serviced wet labs for startups and industrial partners, as well as a community of industry experts and biotech entrepreneurs. The laboratory is located at Oslo Science Park amid Norwegian institutions like University of Oslo, Oslo University Hospital, SINTEF, and a range of life science companies. ShareLab is non-profit and will reinvest profits in cutting edge laboratories and industrial knowhow to help fuel Norwegian life science.

For more information, please visit the website: www.sharelab.no